Hormone receptor-positive, HER2-negative metastatic breast cancer care is rapidly moving from sequencing to a precision framework. First-line CDK4/6 inhibitor-based therapy remains the standard of care, but a new wave of trials shifts the focus to identifying who benefits and when biology should inform treatment optimization. Incorporating biomarker-selected intensification and embedding PROs, PREMs, and quality-adjusted endpoints more closely align treatment with what patients value.
Cosimo et al. (Tue,) studied this question.